α-synuclein seed amplification in Parkinson's disease - Authors' reply

Affiliations

¹ Department of Neurology, Penn Perelman School of Medicine, Philadelphia, PA 19107, USA. Electronic address: siderowf@upenn.edu.
² Research and Development Unit, Amprion, San Diego, CA, USA.
³ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
⁴ Department of Neurology, University of Texas McGovern Medical School at Houston, TX, USA.

Comment

Andrew Siderowf et al. Lancet Neurol. 2023 Nov.

. 2023 Nov;22(11):985-986.

doi: 10.1016/S1474-4422(23)00371-X.

¹ Department of Neurology, Penn Perelman School of Medicine, Philadelphia, PA 19107, USA. Electronic address: siderowf@upenn.edu.
² Research and Development Unit, Amprion, San Diego, CA, USA.
³ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
⁴ Department of Neurology, University of Texas McGovern Medical School at Houston, TX, USA.

No abstract available

Comment on

α-synuclein seed amplification in Parkinson's disease.
Couto B, Marras C, Di Luca DG. Couto B, et al. Lancet Neurol. 2023 Nov;22(11):983-984. doi: 10.1016/S1474-4422(23)00372-1. Lancet Neurol. 2023. PMID: 37863602 No abstract available.
α-synuclein seed amplification in Parkinson's disease.
Mestre TA, Kalia LV. Mestre TA, et al. Lancet Neurol. 2023 Nov;22(11):984-985. doi: 10.1016/S1474-4422(23)00374-5. Lancet Neurol. 2023. PMID: 37863603 No abstract available.
α-synuclein seed amplification in Parkinson's disease.
Beach TG, Adler CH, Shill HA, Serrano GE, Zhang N. Beach TG, et al. Lancet Neurol. 2023 Nov;22(11):985. doi: 10.1016/S1474-4422(23)00373-3. Lancet Neurol. 2023. PMID: 37863604 No abstract available.